Clinical Trials Search at Vanderbilt-Ingram Cancer Center

A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/=1 to <31 Years Old with First Relapse

Disease Sites:

Not Available

Staging:

Phase II

Age Group:

Both

Therapies:

Not Available

Drugs:

Not Available

Principal Investigator(s):

Not Available

Scope:

National

Participating Institutions:

Vanderbilt University

Open Date:

04-09-2021

Trial Type:

Treatment

Protocol ID:

COGAALL1821

National Clinical Trial ID:

NCT04546399

Related Internal Documents:

View Internal Documents

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available